Table 4.
Summary of TRAEs after PSM.
| Event, n (%) | Chemotherapy (n=20) | DEB-TACE+ICIs (n=20) | P | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TRAE | Any grade | Grade 1/2 | Grade 3/4 | Any grade | Grade 1/2 | Grade 3/4 | Any grade | Grade 1/2 | Grade 3/4 | ||
| 20(100.0) | 17 (85.0) | 8 (40.0) | 17 (85.0) | 16 (80.0) | 6 (30.0) | 0.072 | 0.677 | 0.507 | |||
| Hematologic toxic effects | |||||||||||
| Leukopenia Neutropenia Reduced hemoglobin level Thrombocytopenia |
8 (40.0) 7 (35.0) 3 (15.0) 6 (30.0) |
6 (30.0) 6 (30.0) 2 (10.0) 5 (25.0) |
2 (10.0) 1 (5.0) 1 (5.0) 1 (5.0) |
2 (10.0) 1 (5.0) 1 (5.0) 2 (10.0) |
1 (5.0) 1 (5.0) 1 (5.0) 2 (10.0) |
0 (0) 0 (0) 0 (0) 0 (0) |
0.028 0.018 0.292 0.114 |
0.037 0.037 0.548 0.212 |
0.147 0.311 0.311 0.311 |
||
| Hepatic function | |||||||||||
| Increased AST Increased ALT |
5 (25.0) 5 (25.0) |
3(15.0) 3 (15.0) |
2 (10.0) 2 (10.0) |
9(45.0) 9 (45.0) |
6 (30.0) 5 (25.0) |
3(15.0) 4 (20.0) |
0.185 0.185 |
0.256 0.429 |
0.633 0.376 |
||
| Hyperbilirubinemia Hypoalbuminemia |
4 (20.0) 4 (20.0) |
4 (20.0) 4 (20.0) |
0 (0) 0 (0) |
6 (30.0) 5 (25.0) |
6 (30.0) 5 (25.0) |
0 (0) 0 (0) |
0.465 0.705 |
0.465 0.705 |
>0.999 >0.999 |
||
| Nonhematologic toxic effects | |||||||||||
| Nausea Vomiting Anorexia Fatigue Constipation Abdominal pain Alopecia Rash Hypothyroidism RCCEP |
8 (40.0) 9 (45.0) 4 (20.0) 7 (35.0) 1 (5.0) 3 (15.0) 3 (15.0) 1 (5.0) 0 (0) 0 (0) |
8 (40) 7 (35.0) 4 (20.0) 4 (20.0) 1 (5.0) 3 (15.0) 2 (10.0) 1 (5.0) 0 (0) 0 (0) |
0 (0) 2(10.0) 0 (0) 3 (15.0) 0 (0) 0 (0) 1 (5.0) 0 (0) 0 (0) 0 (0) |
6 (30.0) 8 (40.0) 2 (10.0) 8 (40.0) 2 (10.0) 6 (30.0) 2 (10.0) 3 (15.0) 5 (25.0) 5 (25.0) |
6 (30.0) 6 (30.0) 2 (10.0) 5 (25.0) 2 (10.0) 4 (20.0) 2 (10.0) 3 (15.0) 5 (25.0) 5 (25.0) |
0 (0) 2 (10.0) 0 (0) 3 (15.0) 0 (0) 2 (10.0) 0 (0) 0 (0) 0 (0) 0 (0) |
0.507 0.749 0.376 0.744 0.548 0.256 0.633 0.292 0.017 0.017 |
0.507 0.736 0.376 0.705 0.548 0.677 >0.999 0.292 0.017 0.017 |
>0.999 >0.999 >0.999 >0.999 >0.999 0.147 0.311 >0.999 >0.999 >0.999 |
||
TRAEs, treatment-related adverse events; PSM, propensity score matching; TRAE, treatment-related adverse event; DEB-TACE+ICIs, drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors; AST, aspartate aminotransferase; ALT, alanine transaminase; RCCEP, reactive cutaneous capillary endothelial proliferation.